Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
暂无分享,去创建一个
A. Antoszyk | C. Chung | Carol Y Chung | L. Tuomi | Andrew N Antoszyk | Lisa Tuomi | Angele Singh | Angele Singh
[1] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[2] R. Nussenblatt,et al. Uveitis: Fundamentals and Clinical Practice , 1988 .
[3] N. Bressler. Age-related macular degeneration is the leading cause of blindness... , 2004, JAMA.
[4] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[5] Ursula Schmidt-Erfurth,et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes , 2002, Graefe’s Archive for Clinical and Experimental Ophthalmology.
[6] Jennifer I. Lim,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report , 2004, Retina.
[7] J. Hecht,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[9] M. C. Leske,et al. Prevalence of open-angle glaucoma among adults in the United States. , 2004, Archives of ophthalmology.
[10] Simon P. Harding,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.
[11] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[12] M. Blumenkranz,et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. , 2005, Ophthalmology.
[13] A. D. de Vos,et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.
[14] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[15] N. Bressler. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.
[16] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[17] L. Yannuzzi. A new standard of care for laser photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Data revisited. , 1994, Archives of ophthalmology.
[18] P. Rosenfeld,et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[19] F. Holz,et al. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). , 2003, Ophthalmology.
[20] M. Hogan,et al. Signs and symptoms of uveitis. I. Anterior uveitis. , 1959, American journal of ophthalmology.
[21] David H. Johnson,et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy , 2005 .
[22] Irene Barbazetto,et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. , 2003, Archives of ophthalmology.
[23] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[24] P. Kaiser,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[25] J. P. Sy,et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.
[26] C. Margo,et al. Choroidal neovascular membranes: reproducibility of angiographic interpretation. , 2000, American journal of ophthalmology.
[27] S. Harding. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials¿TAP Report No. 5 , 2002 .
[28] C. Regillo,et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.
[29] F. Ferris,et al. Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.
[30] R. Ritch. Pigment dispersion syndrome. , 1998, American journal of ophthalmology.
[31] R. Klein,et al. Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.
[32] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[33] S. Resnikoff,et al. Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.
[34] T. Ciulla,et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.